AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38458769 — intervention group
Group type: COMPARATOR
Intervention: average systolic FD (FDsavg)
Number of subjects: 15
Study 38458769 — intervention group
Group type: COMPARATOR
Intervention: ΔsRA
Number of subjects: 15
Study 38458783 — intervention group
Group type: EXPERIMENTAL
Intervention: Revealed screening with sFlt-1/PlGF ratio
Number of subjects: 0
Study 38458783 — intervention group
Group type: COMPARATOR
Intervention: Concealed screening (unknown sFlt-1/PlGF ratio)
Number of subjects: 0
Study 38458786 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) with health education
Number of subjects: 256
Study 38458786 — intervention group
Group type: COMPARATOR
Intervention: Superficial acupuncture (SA) with health education
Number of subjects: 256
Study 38458786 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 256
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical KOA at baseline
Number of subjects: 178
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 178
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral fat area (VFA)
Number of subjects: 178
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse knee pain intensity
Number of subjects: 178
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS Pain score
Number of subjects: 178
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS Symptoms score
Number of subjects: 178
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS Activities of daily living score
Number of subjects: 178
Study 38458788 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS Quality of Life score
Number of subjects: 178
Study 38458796 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 0
Study 38458796 — intervention group
Group type: COMPARATOR
Intervention: Other antihypertensive medicines (AHT)
Number of subjects: 0
Study 38458811 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of long bone fractures and traumatic hip dislocations in paediatric patients
Number of subjects: 750
Study 38458816 — intervention group
Group type: EXPERIMENTAL
Intervention: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor, GM-CSF)
Number of subjects: 60
Study 38458816 — intervention group
Group type: EXPERIMENTAL
Intervention: PRaG regimen (thymalfasin, PD-1/PD-L1 inhibitor)
Number of subjects: 60
Study 38459049 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular care with additional videoconference consultations (VCG)
Number of subjects: 56
Study 38459049 — intervention group
Group type: COMPARATOR
Intervention: Regular care group (RCG)
Number of subjects: 56
Study 38459072 — intervention group
Group type: EXPERIMENTAL
Intervention: S. sonnei Generalized Modules for Membrane Antigen (GMMA)-based vaccine (1790GAHB)
Number of subjects: 0
Study 38459072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38459156 — intervention group
Group type: EXPERIMENTAL
Intervention: R-GemOx (Rituximab, gemcitabine, and oxaliplatin)
Number of subjects: 55
Study 38459160 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniMed 780G
Number of subjects: 29
Study 38459254 — intervention group
Group type: EXPERIMENTAL
Intervention: Spurs and build-ups (SBU)
Number of subjects: 0
Study 38459254 — intervention group
Group type: COMPARATOR
Intervention: Spurs only (S)
Number of subjects: 0
Study 38459338 — intervention group
Group type: EXPERIMENTAL
Intervention: INS018_055 (small-molecule TNIK inhibitor)
Number of subjects: 78
Study 38459338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 38459353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dating Matters intervention
Number of subjects: 46
Study 38459353 — intervention group
Group type: COMPARATOR
Intervention: Standard of care intervention
Number of subjects: 46
Study 38459510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory (PedsQL)
Number of subjects: 512
Study 38459510 — intervention group
Group type: EXPERIMENTAL
Intervention: 16D
Number of subjects: 512
Study 38459510 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 512
Study 38459510 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of HRQoL by condition
Number of subjects: 512
Study 38459510 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between PedsQL and 16D
Number of subjects: 512
Study 38459552 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA-IM)
Number of subjects: 398
Study 38459552 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (IUD)
Number of subjects: 398
Study 38459552 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 398
Study 38459579 — intervention group
Group type: EXPERIMENTAL
Intervention: BAI + SFAS
Number of subjects: 525
Study 38459579 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + SFAS
Number of subjects: 525
Study 38459579 — intervention group
Group type: COMPARATOR
Intervention: Education Control
Number of subjects: 525
Study 38459584 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based MRI-only workflow with synthetic CT (sCT) derived from MRI DIXON-sequence
Number of subjects: 54
Study 38459584 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy and imaging including both CT and MRI
Number of subjects: 54
Study 38459585 — intervention group
Group type: EXPERIMENTAL
Intervention: Asfotase alfa for ≥ 6 months
Number of subjects: 190
Study 38459598 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 expression detection
Number of subjects: 30
Study 38459686 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexor maximal isometric strength in the injured limb of individuals with CAI
Number of subjects: 30
Study 38459686 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal isometric strength of knee extensor muscles
Number of subjects: 30
Study 38459686 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal isometric contractions at 20%, 50%, and 80% of maximal voluntary isometric contraction
Number of subjects: 30
Study 38459686 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor and flexor muscle activation
Number of subjects: 30
Study 38459869 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan (TPZ), amoxicillin, clarithromycin, and bismuth (300 mg twice daily)
Number of subjects: 306
Study 38459869 — intervention group
Group type: COMPARATOR
Intervention: Tegoprazan (TPZ), amoxicillin, and clarithromycin (without bismuth)
Number of subjects: 306
Study 38460070 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 genes
Number of subjects: 467
Study 38460070 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of statins
Number of subjects: 467
Study 38460070 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of nitrofurantoin
Number of subjects: 467
Study 38460082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ensitrelvir 375 mg single dose
Number of subjects: 0
Study 38460092 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone treatment (GAHT) in transgender women (TW) after sex hormone inhibition and estradiol treatment.
Number of subjects: 32
Study 38460092 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone treatment (GAHT) in transgender men (TM) after estrogen suppression and testosterone treatment.
Number of subjects: 32
Study 38460092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effects of GAHT on adipose tissue function in both TW and TM.
Number of subjects: 32
Study 38460107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (LEM)
Number of subjects: 90
Study 38460161 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 600
Study 38460161 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 600
Study 38460193 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% trichloroacetic acid + 3% glycolic acid chemical peel
Number of subjects: 20
Study 38460193 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated hand)
Number of subjects: 20
Study 38460525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent vaccine (NVX-CoV2373 + NVX-CoV2540)
Number of subjects: 766
Study 38460525 — intervention group
Group type: COMPARATOR
Intervention: Prototype vaccine (NVX-CoV2373)
Number of subjects: 766
Study 38460548 — intervention group
Group type: EXPERIMENTAL
Intervention: riociguat
Number of subjects: 121
Study 38460548 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study 38460754 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nudges delivered via the Danish governmental electronic letter system
Number of subjects: 1182254
Study 38460754 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no electronic letter)
Number of subjects: 1182254
Study 38460823 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaerythrityl tetranitrate
Number of subjects: 240
Study 38460823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 38460974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MI-E) delivered by an experienced physiotherapist, with four cycles at a range of prescriptions.
Number of subjects: 0
Study 38460974 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal endoscopy used to visualize the larynx during MI-E.
Number of subjects: 0
Study 38460974 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessments of spirometry, peak cough flow, and sniff nasal inspiratory pressure.
Number of subjects: 0
Study 38461094 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-mg daily aspirin
Number of subjects: 134
Study 38461094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 38461275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention (CTSP) + Services as Usual (SAU) (N=150)
Number of subjects: 300
Study 38461275 — intervention group
Group type: COMPARATOR
Intervention: Services as Usual (SAU) alone (N=150)
Number of subjects: 300
Study 38461313 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml natural aronia juice (verum, V) twice daily
Number of subjects: 40
Study 38461313 — intervention group
Group type: COMPARATOR
Intervention: Polyphenol-free placebo (P)
Number of subjects: 40
Study 38461323 — intervention group
Group type: EXPERIMENTAL
Intervention: neoadjuvant pertuzumab with trastuzumab and docetaxel
Number of subjects: 329
Study 38461323 — intervention group
Group type: COMPARATOR
Intervention: neoadjuvant placebo with trastuzumab and docetaxel
Number of subjects: 329
Study 38461348 — intervention group
Group type: EXPERIMENTAL
Intervention: Run, Jump & Fun intervention (4×30 min/week of moderate-to-vigorous physical activity)
Number of subjects: 0
Study 38461348 — intervention group
Group type: EXPERIMENTAL
Intervention: Move & Learn intervention (4×30 min/week focusing on embodied learning in math and Danish lessons)
Number of subjects: 0
Study 38461348 — intervention group
Group type: COMPARATOR
Intervention: Control condition (normal teaching practices)
Number of subjects: 0
Study 38461480 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive PCR tests at follow-up (3, 6, and 9 months)
Number of subjects: 1008
Study 38461480 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive IgG tests at baseline and follow-up (3, 6, and 9 months)
Number of subjects: 1008
Study 38461480 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention of positive IgG
Number of subjects: 1008
Study 38461480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination status
Number of subjects: 1008
Study 38461480 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up of IgG seroconversion
Number of subjects: 1008
Study 38461657 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated initiation of renal-replacement therapy (RRT)
Number of subjects: 2141830
Study 38461657 — intervention group
Group type: COMPARATOR
Intervention: Standard initiation of renal-replacement therapy (RRT)
Number of subjects: 2141830
Study 38461731 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone add-on 10-mg three times daily for 16 weeks
Number of subjects: 17
Study 38461731 — intervention group
Group type: COMPARATOR
Intervention: No add-on treatment (control)
Number of subjects: 17
Study 38461731 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 17
Study 38461841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 12 weeks (8q12)
Number of subjects: 1011
Study 38461841 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 16 weeks (8q16)
Number of subjects: 1011
Study 38461841 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2 mg every 8 weeks (2q8)
Number of subjects: 1011
Study 38461841 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 8 mg every 12 weeks (8q12) vs 2q8
Number of subjects: 1011
Study 38461841 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 8 mg every 16 weeks (8q16) vs 2q8
Number of subjects: 1011
Study 38461841 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1011
Study 38461843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 12 weeks (8q12)
Number of subjects: 660
Study 38461843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 8 mg every 16 weeks (8q16)
Number of subjects: 660
Study 38461843 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept 2 mg every 8 weeks (2q8)
Number of subjects: 660
Study 38461843 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 660
Study 38461957 — intervention group
Group type: EXPERIMENTAL
Intervention: TTA-121 6U/day for 4 weeks
Number of subjects: 207
Study 38461957 — intervention group
Group type: COMPARATOR
Intervention: Syntocinon 48U/day for 4 weeks
Number of subjects: 207
Study 38461957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 38462160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic congestion endotype (n=75)
Number of subjects: 145
Study 38462160 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume overload congestion endotype (n=50)
Number of subjects: 145
Study 38462160 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic congestion endotype (n=20)
Number of subjects: 145
Study 38462218 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic formula (GOS/Limosilactobacillus fermentum CECT 5716)
Number of subjects: 460
Study 38462218 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 460
Study 38462218 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 460
Study 38462256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafoxiparin (60 mg daily as 0.4 mL subcutaneous injections until labor onset, maximum 28 days)
Number of subjects: 624
Study 38462256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafoxiparin (initial bolus of 7, 21, or 35 mg followed by continuous infusion at 5, 15, or 25 mg/hour until delivery; maximum duration 36 hours)
Number of subjects: 624
Study 38462256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 38462265 — intervention group
Group type: EXPERIMENTAL
Intervention: OdonAssist inflatable device
Number of subjects: 104
Study 38462389 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCA guided selective ICA
Number of subjects: 343
Study 38462389 — intervention group
Group type: COMPARATOR
Intervention: ICA alone
Number of subjects: 343
Study 38462426 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam tape application (2 x 2 inch piece of 3 M microfoam adhesive applied to the medial aspect of the upper arm for 48 hours)
Number of subjects: 40
Study 38462426 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam tape application
Number of subjects: 40
Study 38462613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (IDI)
Number of subjects: 15
Study 38462625 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant
Number of subjects: 1550
Study 38462625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1550
Study 38462625 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 1550
Study 38462673 — intervention group
Group type: COMPARATOR
Intervention: 600 mg rifampicin daily (flat dose)
Number of subjects: 680
Study 38462751 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regimen containing high-dose moxifloxacin and clofazimine
Number of subjects: 200
Study 38462751 — intervention group
Group type: COMPARATOR
Intervention: Long regimen
Number of subjects: 200
Study 38462760 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP use by partner(s)
Number of subjects: 609
Study 38462760 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent condom use (ICU)
Number of subjects: 609
Study 38462760 — intervention group
Group type: EXPERIMENTAL
Intervention: STI incidence
Number of subjects: 609
Study 38462760 — intervention group
Group type: EXPERIMENTAL
Intervention: Age below 35 years, not being in a stable relationship, higher number of sexual partners
Number of subjects: 609
Study 38462760 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as prevention (TasP)
Number of subjects: 609
Study 38462760 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 609
Study 38462764 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag, daily fixed-dose for 6 months
Number of subjects: 15
Study 38462919 — intervention group
Group type: EXPERIMENTAL
Intervention: ATI-free diet
Number of subjects: 45
Study 38462987 — intervention group
Group type: EXPERIMENTAL
Intervention: T-TEER (tricuspid transcatheter edge-to-edge repair)
Number of subjects: 20
Study 38462987 — intervention group
Group type: EXPERIMENTAL
Intervention: T-TEER
Number of subjects: 20
Study 38463163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed RV1-RV5 vaccine schedules
Number of subjects: 1498
Study 38463163 — intervention group
Group type: COMPARATOR
Intervention: Standard RV1 and RV5 schedules
Number of subjects: 1498
Study 38463415 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumatic Brain Injury (TBI) group
Number of subjects: 168
Study 38463464 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy (performed within 72 hours after randomization)
Number of subjects: 0
Study 38463464 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy (performed 30±5 days after randomization)
Number of subjects: 0
Study 38463464 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 0
Study 38463464 — intervention group
Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 0
Study 38463541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks) + External Beam Radiation Therapy (EBRT, median dose: 50 Gy)
Number of subjects: 50
Study 38463677 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex percutaneous coronary intervention (C-PCI)
Number of subjects: 11714
Study 38463677 — intervention group
Group type: EXPERIMENTAL
Intervention: High platelet reactivity (HPR)
Number of subjects: 11714
Study 38463680 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR measurement
Number of subjects: 2965
Study 38463680 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR ≤0.80
Number of subjects: 2965
Study 38463680 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR
Number of subjects: 2965
Study 38463683 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR-guided PCI
Number of subjects: 3825
Study 38463683 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 3825
Study 38464052 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG)
Number of subjects: 51
Study 38464052 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 51
Study 38464207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of 131I-omburtamab
Number of subjects: 4
Study 38464979 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38465503 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health intervention (specific details not available)
Number of subjects: 0
Study 38465503 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not available)
Number of subjects: 0
Study 38465515 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraglutide 5 mg administered subcutaneously
Number of subjects: 2
Study 38465515 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers with normal renal function
Number of subjects: 2
Study 38465592 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 4393
Study 38465592 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 4393
Study 38465592 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes status
Number of subjects: 4393
Study 38465623 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-enriched salt
Number of subjects: 20995
Study 38465623 — intervention group
Group type: COMPARATOR
Intervention: Regular salt
Number of subjects: 20995
Study 38465885 — intervention group
Group type: EXPERIMENTAL
Intervention: Foslevodopa/foscarbidopa
Number of subjects: 0
Study 38466118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung microbiota characteristics in patients with low respiratory system compliance (Crs) and low ventilatory ratio (VR) characterized by Proteobacteria dominance.
Number of subjects: 70
Study 38466118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung microbiota characteristics
Number of subjects: 70
Study 38466118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung microbiota diversity
Number of subjects: 70
Study 38466203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training (6 weeks, 3 days/week)
Number of subjects: 40
Study 38466203 — intervention group
Group type: COMPARATOR
Intervention: Control group (awareness sessions about diabetes and foot care for 30 mins, every 2 weeks)
Number of subjects: 40